Argenx's Drug Scores European Approval For Muscular Fatigue Disorder

The European Commission has approved Argenx SE's ARGX Vyvgart (efgartigimod alfa-fcab) as an add-on to standard therapy for generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody positive.
gMG is characterized by weakness and rapid fatigue of any of the muscles under voluntary control. It's caused by a breakdown in the regular communication between nerves and muscles.
Related: Argenx's Vyvgart To 'Achieve Blockbuster Status,' This Analyst Says With 6% Price Target Hike.
Argenx's plans remain on track to launch Vyvgart in Canada and China through its collaboration with Zai Lab Limited ZLAB and in select additional regions.
The approval is based on results from the Phase 3 ADAPT trial demonstrating that 68% of the patients were responders on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale following treatment with efgartigimod compared to 30% on placebo.
Price Action: ARGX shares are up 1.29% at $379.08 on the last check Thursday.